相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis
Ruojing Bai et al.
BMC INFECTIOUS DISEASES (2022)
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
A. Turkova et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed Adolescents
Neil Thivalapill et al.
CLINICAL INFECTIOUS DISEASES (2021)
Weight gain and integrase inhibitors
Allison Ross Eckard et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2020)
Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy
Leonardo Calza et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Switching to Integrase Inhibitors Unlinked to Weight Increase in Perinatally HIV-Infected Young Adults and Adolescents: A 10-Year Observational Study
Lucia Taramasso et al.
MICROORGANISMS (2020)
Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus
Jordi Navarro et al.
PHARMACOTHERAPY (2019)
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
Willem D. F. Venter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
Pedro Cahn et al.
LANCET (2019)
Effect of HIV infection and antiretroviral therapy on immune cellular functions
Marek Korencak et al.
JCI INSIGHT (2019)
Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients
Pilar Vizcarra et al.
ANTIVIRAL THERAPY (2019)
Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals
Kellie L. Hawkins et al.
ANTIVIRAL THERAPY (2019)
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication
A. Borghetti et al.
HIV MEDICINE (2018)
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
Josep M. Llibre et al.
LANCET (2018)
Simplification to dual therapy (atazanavir/ritonavir plus lamivudine) versus standard triple therapy [atazanavir/ritonavir plus two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
J. A. Perez-Molina et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
Jose R. Arribas et al.
LANCET INFECTIOUS DISEASES (2015)
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study
Jean-Michel Molina et al.
LANCET HIV (2015)
分享论文
